Sector News

AstraZeneca divests asthma and rhinitis drug rights to Covis Pharma

December 7, 2018
Life sciences

AstraZeneca has completed its $350m sale of its rights to asthma drug Alvesco (ciclesonide) and nasal sprays Omnaris and Zetonna (ciclesonide) to Switzerland-based Covis Pharma.

The divested rights by the UK-based AstraZeneca to Covis Pharma cover markets outside the US and the US royalties for the three over-the-counter (OTC) drugs.

In 2017, AstraZeneca earned a combined $106m from the sales of Alvesco, Zetonna and Omnaris.

Alvesco is an inhaled anti-inflammatory maintenance therapy that is administered through a metered-dose inhaler to help control persistent asthma.

Both Omnaris and Zetonna were developed for the treatment of nasal symptoms resulting from seasonal allergic and allergic/non-allergic perennial rhinitis.

The active ingredient across all the three OTC drugs is ciclesonide, a synthetic corticosteroid that is known to play a role in reducing inflammation.

The deal, which was announced in November 2018, does not include the transfer of any employees or facilities of the pharma major to the Swiss company.

As per the terms of the deal, Covis Pharma will also make conditional sales-related payments for the three drugs of up to $21m to AstraZeneca over four years starting from 2019.

Last year, the Swiss pharma company acquired the US market rights of ciclesonide products Alvesco (ciclesonide) Inhalation Aerosol, Omnaris (ciclesonide) Nasal Spray, and Zetonna (ciclesonide) Nasal Aerosol from Sunovion Pharmaceuticals.

For AstraZeneca, the sale of the asthma and rhinitis drug rights to Covis Pharma is part of its strategic objectives to divest parts of its portfolio to allocate resources to develop new medicines to address unmet patient needs.

AstraZeneca, in a statement, said: “As AstraZeneca will not maintain a significant ongoing interest in the medicines, the upfront payment, net of a significant, non-cash derecognition of an intangible asset will be reported as Other Operating Income & Expense in the Company’s financial statements in the fourth quarter of 2018. The agreement does not affect the Company’s financial guidance for 2018.”

Last month, the company agreed to divest the US rights of its respiratory drug Synagis (palivizumab) to Swedish Orphan Biovitrum (Sobi) in a deal worth $1.5bn.

Source: PBR

comments closed

Related News

April 20, 2024

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Life sciences

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

April 20, 2024

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

Life sciences

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

April 20, 2024

Sanofi cuts staff in Belgium as early-stage research dwindles

Life sciences

Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.

How can we help you?

We're easy to reach